Esophageal cancer future or investigational therapies

Jump to navigation Jump to search

Esophageal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Esophageal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esophageal cancer future or investigational therapies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Esophageal cancer future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esophageal cancer future or investigational therapies

CDC on Esophageal cancer future or investigational therapies

Esophageal cancer future or investigational therapies in the news

Blogs on Esophageal cancer future or investigational therapies

Directions to Hospitals Treating Esophageal cancer

Risk calculators and risk factors for Esophageal cancer future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Future Therapies

  • Advances in the treatment of esophageal cancer are focused on:[1]
    • Fusion FDG- PET scanning for accurate staging
    • Immunotherapy checkpoint inhibitor such as pembrolizumab (Keytruda) that targets the programmed cell death - 1 (PD-1) receptor on the lymphocytes.
  • Recent developments include the analyzation of NY-ESO-1 cancer-testis (CT) antigen expression in esophageal cancer.[2]
    • The high expression frequency of NY-ESO-1 in esophageal cancer could mean the development of a vaccine.

References

  1. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009). "Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria". Clin. Cancer Res. 15 (23): 7412–20. doi:10.1158/1078-0432.CCR-09-1624. PMID 19934295.
  2. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM (2012). "CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1". Cancer Res. 72 (4): 887–96. doi:10.1158/0008-5472.CAN-11-2637. PMC 3288235. PMID 22205715.


Template:WikiDoc Sources